PGX (Y-BG) commercial plant in GermanyCZO's work on the COVID inhalable therapeutic must have incited the decision to move forth on equipment and site selection in Germany in advance of a PGX signed deal.
It was less than a month ago that CZO announced the advancement of the inhalable therapeutic;
With the expected completion of the third and fourth goals related to tolerability, safety and efficacy studies with both nave and pre-clinical animal models as early as mid-October, our teams are positioning us to be ahead of schedule. Hoping for favorable pre-clinical results, preparations of a Phase 1/2 clinical trial protocol will be commenced immediately and planned to be submitted to Health Authorities during Q4 2020. Given that yeast beta-glucan is already approved as a pharmaceutical additive, we expect to quickly develop PGX-YBG as a fast-acting inhalable stand-alone therapeutic and/or delivery system to treat severe inflammation observed in COVID-19 patients and other fibrotic end-point disease in the lung,
The share price has advanced slowly and surely since late May, perhaps we will see an acceleration in the share price momentum as they move forward.